Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
← catalyst calendarNCT05891171 · readout ≤ 406 d
Sponsored by Arcus Biosciences, Inc. (industry) · RCUS — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
40actual
Sites
14
Countries
Australia, Taiwan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-13 | actual | When the study began enrolling |
| Primary completion | Sep 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Cancer
- Advanced Malignancies
- Bladder Cancer
- Cervical Cancer
- Esophageal Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer (GEJ)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Non-Small Cell Lung Cancer (NSCLC)
- Ovarian Cancer
- Renal Cell Carcinoma (RCC)
- Triple Negative Breast Cancer (TNBC)
Interventions
- Drug: AB598
- Drug: Zimberelimab — also filed as AB122
- Drug: Fluorouracil
- Drug: Leucovorin
- Drug: Oxaliplatin
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Up to 2 years
Dose Escalation Cohorts: Number of Participants with Dose-Limiting Toxicities (DLTs)
measured Up to 2 years
Permalink · RCUS's whole pipeline · Catalyst calendar · Every registered study · What changed